BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23152765)

  • 21. Improved peak detection and quantification of mass spectrometry data acquired from surface-enhanced laser desorption and ionization by denoising spectra with the undecimated discrete wavelet transform.
    Coombes KR; Tsavachidis S; Morris JS; Baggerly KA; Hung MC; Kuerer HM
    Proteomics; 2005 Nov; 5(16):4107-17. PubMed ID: 16254928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry.
    Liu XP; Shen J; Li ZF; Yan L; Gu J
    Cancer Invest; 2006 Dec; 24(8):747-53. PubMed ID: 17162557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry serum protein profiling to identify nasopharyngeal carcinoma.
    Ho DW; Yang ZF; Wong BY; Kwong DL; Sham JS; Wei WI; Yuen AP
    Cancer; 2006 Jul; 107(1):99-107. PubMed ID: 16708360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mass spectrometry data processing using zero-crossing lines in multi-scale of Gaussian derivative wavelet.
    Nguyen N; Huang H; Oraintara S; Vo A
    Bioinformatics; 2010 Sep; 26(18):i659-65. PubMed ID: 20823336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry coupled with an artificial neural network model for the diagnosis of hepatocellular carcinoma.
    Hu Q; Huang Y; Wang Z; Tao H; Liu J; Yan L; Wang K
    Hepatogastroenterology; 2012 Sep; 59(118):1902-6. PubMed ID: 22193438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benchmarking currently available SELDI-TOF MS preprocessing techniques.
    Emanuele VA; Gurbaxani BM
    Proteomics; 2009 Apr; 9(7):1754-62. PubMed ID: 19294696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers.
    Ball G; Mian S; Holding F; Allibone RO; Lowe J; Ali S; Li G; McCardle S; Ellis IO; Creaser C; Rees RC
    Bioinformatics; 2002 Mar; 18(3):395-404. PubMed ID: 11934738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative quality-assessment techniques to compare fractionation and depletion methods in SELDI-TOF mass spectrometry experiments.
    Harezlak J; Wang M; Christiani D; Lin X
    Bioinformatics; 2007 Sep; 23(18):2441-8. PubMed ID: 17626063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimization of SELDI-TOF protein profiling for analysis of cervical mucous.
    Panicker G; Lee DR; Unger ER
    J Proteomics; 2009 Jan; 71(6):637-46. PubMed ID: 19064004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach.
    de Seny D; Fillet M; Meuwis MA; Geurts P; Lutteri L; Ribbens C; Bours V; Wehenkel L; Piette J; Malaise M; Merville MP
    Arthritis Rheum; 2005 Dec; 52(12):3801-12. PubMed ID: 16320331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preanalytical and analytical variation of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry of human serum.
    Albrethsen J; Bøgebo R; Olsen J; Raskov H; Gammeltoft S
    Clin Chem Lab Med; 2006; 44(10):1243-52. PubMed ID: 17032137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples.
    Freed GL; Cazares LH; Fichandler CE; Fuller TW; Sawyer CA; Stack BC; Schraff S; Semmes OJ; Wadsworth JT; Drake RR
    Laryngoscope; 2008 Jan; 118(1):61-8. PubMed ID: 18043497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of serum biomarkers for lung cancer using magnetic bead-based SELDI-TOF-MS.
    Song QB; Hu WG; Wang P; Yao Y; Zeng HZ
    Acta Pharmacol Sin; 2011 Dec; 32(12):1537-42. PubMed ID: 22019958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker.
    Chen L; Ho DW; Lee NP; Sun S; Lam B; Wong KF; Yi X; Lau GK; Ng EW; Poon TC; Lai PB; Cai Z; Peng J; Leng X; Poon RT; Luk JM
    Ann Surg Oncol; 2010 Sep; 17(9):2518-25. PubMed ID: 20354800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of software tools to improve the detection of carcinogen induced changes in the rat liver proteome by analyzing SELDI-TOF-MS spectra.
    Beyer S; Walter Y; Hellmann J; Kramer PJ; Kopp-Schneider A; Kroeger M; Ittrich C
    J Proteome Res; 2006 Feb; 5(2):254-61. PubMed ID: 16457590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of hypopharyngeal squamous cell carcinoma using serum proteomics.
    Zhou L; Cheng L; Tao L; Jia X; Lu Y; Liao P
    Acta Otolaryngol; 2006 Aug; 126(8):853-60. PubMed ID: 16846929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of serum biomarkers for nasopharyngeal carcinoma by proteomic analysis.
    Wei YS; Zheng YH; Liang WB; Zhang JZ; Yang ZH; Lv ML; Jia J; Zhang L
    Cancer; 2008 Feb; 112(3):544-51. PubMed ID: 18085639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor.
    Liu J; Zheng S; Yu JK; Zhang JM; Chen Z
    J Zhejiang Univ Sci B; 2005 Jan; 6(1):4-10. PubMed ID: 15593384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection.
    Yasui Y; Pepe M; Thompson ML; Adam BL; Wright GL; Qu Y; Potter JD; Winget M; Thornquist M; Feng Z
    Biostatistics; 2003 Jul; 4(3):449-63. PubMed ID: 12925511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.
    Zinkin NT; Grall F; Bhaskar K; Otu HH; Spentzos D; Kalmowitz B; Wells M; Guerrero M; Asara JM; Libermann TA; Afdhal NH
    Clin Cancer Res; 2008 Jan; 14(2):470-7. PubMed ID: 18223221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.